Forensic analysis of 38 subject deaths shared by Corinne Michels Writer Science Rules by Corinne Michels, found evidence of an over 3.7-fold increase in number of deaths due to cardiovascular events

in Pfizer (BNT162b2) vaccinated subjects compared to Placebo controls. This significant adverse event signal was not reported by Pfizer/BioNTech.

https://ijvtpr.com/index.php/IJVTPR/article/view/86/224

‘study is a forensic analysis of the 38 trial subjects who died between July 27, 2020, the start of Phase 2/3 of the clinical trial, and March 13, 2021, the end date of theofficial6-Month Interim Report.

Phase 2/3 of the trial involved 44,060subjects who were equally distributed into two groups and received dose1 of either the BNT162b2 mRNA vaccine or a placebo consisting of a 0.9% normal salinesolution. At week 20, when the BNT162b2 mRNA vaccine received Emergency Use Authorization from the US FDA, subjects in the placebo arm were given the option to receive the BNT162b2 vaccine and switch to the vaccinatedgroup.

Of the reported 20,794 unblinded placebo subjects, 19,685 received at least one dose of BNT162b2 vaccine. Surprisingly, a comparison of the number of subject deaths per week during the 33 weeks of this study found no significant difference between the number of deaths in the vaccinated versus placebo arms for the first 20 weeks of the trial—the placebo-controlled portion of the trial. After week 20, as subjects in the placebogroupwere unblinded,and after the majority of them received a BNT162b2 injection, deaths among those sticking with the placebo slowed and eventually plateaued.

Deaths in the BNT162b2 vaccinated subjects continued at the same rate. Our analysis revealsinconsistencies between the subject data listed in the 6-Month Interim Report and in publications authored by Pfizer/BioNTech trial site administrators.

Most importantly, we found evidence of an over 3.7-fold increase in number of deaths due to cardiacevents in the BNT162b2 vaccinated individualscompared to those who received only the placebo.’